drugset / Trial / NCT03825367
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Phase 1/2
Unknown
13 enrolled
Therapeutic Advances in Childhood Leukemia Consortium
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia
Timeline
- Start
- 2019-11-29
- Primary completion
- 2023-05-31
- Completion
- 2024-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 5-Azacytidine | Small molecule | 75 mg/m2 | Subcutaneous |
| Subject | Nivolumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | — |